Zoekresultaten - You searched for Small molecule therapeutics

398 results

New collaboration between VIB and Plant Impact plc: advancing crop enhancement small molecule discovery

Read more

FairJourney Biologics announces an innovative technology to discover antibody molecules in full therapeutic format

Read more

Fibrocor and Galapagos sign partnership in fibrosis

Read more

ThromboGenics Achieves Important Milestone in the Development of THR-149

Read more

Rewind Therapeutics secures 15.2 M EURO to develop novel remyelination therapies

Read more

Scientists expose protein responsible for allergic diseases

Read more

Cell Death and Immunity in Disease: from molecules to translational medicine

Read more

Dosing of First Patient with investigational agent OMO-1

Read more

New start-up Aelin Therapeutics secures 27M Euros to pioneer the development of a novel drug modality

Read more

VIB, CD3 and Galapagos NV enter into a license deal for the development of MALT1 inhibitors

Read more

Mithra announces complex therapeutics update

Read more

VIB, CD3 and Beactica announce drug discovery alliance targeting inflammatory diseases

Read more

Gilead and Galapagos enter into transformative research and development collaboration

Read more

ViroVet and GALVmed to collaborate on novel vaccines for sheep & goats

Read more

Novel Nanobody to start clinical development in osteoarthritis - ablynx to receive €15 Million milestone payment

Read more

Ablynx & Sanofi enter into a strategic collaboration to develop nanobody product candidates

Read more

Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMD

Read more

Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib

Read more

Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus

Read more

Esperite (ESP), The Cell Factory demonstrate anti-inflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy

Read more

Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017

Read more

Researchers gain new insights into the formation of non-pathological amyloids

Read more

Galapagos: New Phase 2 study with filgotinib in non-infectious uveitis

Read more

Ablynx receives fast track designation from the FDA for Caplacizumab for the treatment of acquired TTP

Read more

GREEN-CHEM: towards small footprint solutions

Read more

Confo Therapeutics start onderzoeks-samenwerking met Deens farmabedrijf Lundbeck

Read more

ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting

Read more

ThromboGenics Business Update - Q3 2017

Read more

Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline

Read more

ALBATROSS with GLPG2222 shows positive clinical results in CF patients

Read more

Galapagos exercises co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries

Read more

Confo Therapeutics enters into drug discovery collaboration with Roche

Read more

Galapagos - Positive topline results with GLPG1972 in osteoarthritis patients

Read more

Confo Therapeutics is awarded a EUR 1M grant to increase its screening capabilities

Read more

Trapping multidrug-resistant bacteria in molecular glue

Read more

VIB Plant-derived volatiles may serve as future antifungals

Read more

Ardena acquires ChemConnection adding API expertise

Read more

VIB: Molecular details of protein crystal nucleation uncovered

Read more

Galapagos presents strong disease-modifying effects in preclinical model of osteoarthritis with GLPG1972 at OARSI 2018

Read more

ThromboGenics Business Update - Q1 2018

Read more

Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis patients

Read more

ThromboGenics Business Update - H1 2018

Read more

Galapagos reports initiation of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in osteoarthritis patients

Read more

ONTOFORCE and ChemAxon facilitate linked chemical data search

Read more

Oxurion NV Business Update - Q3 2018

Read more

Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis

Read more

Confo Therapeutics Appoints Frank Landolt as its Chief Counsel Legal & Intellectual Property

Read more

Evotec and Galapagos enter into collaboration in the field of fibrosis

Read more

Galapagos: Firmly on our way to becoming a fully integrated biopharma company

Read more

Oxurion NV Business Update - FY 2018

Read more

VIB: Permit for CRISPR maize field trial that aims to measure climate stress

Read more

Scientists (dis)solve a century-long mystery to treat asthma and airway inflammation

Read more

The future of healthcare is digital

Read more

Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients

Read more

VIB: Waking up sleeping bacteria to fight infections

Read more

TiGenix to participate in key investor conferences in April 2017

Read more

Aratana Therapeutics Provides Update on ENTYCE®

Read more

ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE

Read more

Ablynx achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, New Jersey, USA

Read more

Mithra Strengthens E4 Patent Position in Australian Market

Read more

Ablynx announces 2017 half year results and year-to-date business update

Read more

Biotech Showcase™ 2018

Read more

Sanofi to acquire Ablynx for €3.9 Billion

Read more

new England biolabs® and Bluebee partner to deliver an end-to-end data analysis solution for Nebnext direct® target enrichment

Read more

Previously announced tender offers by Sanofi to acquire Ablynx will commence on april 4, 2018

Read more

Grünenthal en KU Leuven bundelen de krachten om een nieuwe niet-opioïde pijnstiller te ontwikkelen

Read more

Mithra launches capital increase by means of a private placement via an accelerated bookbuild offering

Read more

Mithra signs binding heads of terms for commercialization of Estelle® in South Korea with women's health specialist Hyundai Pharm

Read more

Mithra Finalizes Contract for the Commercialization of Estelle® with South Korean Women's Health Leader Hyundai Pharm

Read more

ActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes

Read more

Biotech Showcase™ 2019

Read more

Imec and CARDIS Partners Develop Unique Photonic-Based Medical Device for the Screening

Read more

Mithra Successfully Produces its First Commercial Batch of Myring™ for Europe

Read more

Promethera Biosciences Completes €39.7 Million ($44.4 Million) Series D Financing

Read more

flanders.bio provides you with insights in the vibrant life sciences sector

Read more

Galapagos: Publication of the annual report

Read more

BioBase4SME Natural Fibertastic Workshop aims to encourage SMEs to apply for fully funded Bio-Innovation Coupons for fibre application testing

Read more

TiGenix reports 2016 full year results

Read more

Galapagos increases share capital through warrant exercises

Read more

Data Transparency in Pharma R&D - Update on Policy 70 and first practical experiences

Read more

Bootcamp in Entrepreneurial Innovation in Orphan Diseases

Read more

Galapagos raises $338 million gross proceeds in a U.S. public offering

Read more

Galapagos announces launch of proposed public offering

Read more

Biogazelle offers unique mRNA sequencing on plasma

Read more

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million

Read more

Galapagos announces capital increase

Read more

Esperite N.V. with CryoSave contributes to treating a 9 year old child with thalassema major in Switzerland

Read more

Biocartis Group NV: Biocartis Q1 2017 Business Update

Read more

Galapagos reports first quarter 2017 results

Read more

Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI

Read more

ABLYNX COMPLETES PATIENT RECRUITMENT IN ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF aTTP

Read more

MDxHealth Trading Update: January to April 2017

Read more

Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology

Read more

Galapagos NV: Seven abstracts on filgotinib accepted by EULAR 2017

Read more

Multiplicom launches complete CE-IVD marked solution in Europe for all BRCA testing needs

Read more

Overnight skin care

Read more

Market of 105 billion euros open to Flemish biotech companies

Read more

Galapagos to hold Annual R&D Update 2017 on 20 June

Read more

Ecosynth moves to new laboratories

Read more

Galapagos creates new warrant plan

Read more

Biocartis Group NV: MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Read more

Biocartis launches CE-marked IVD test for lung cancer

Read more

Ablynx appoints Markus Ewert as Chief Business Officer

Read more

Kiadis Pharma raises €5 million in private placement with institutional investors

Read more

VITO sterk in ontwikkeling van dierproefvervangende testmethoden

Read more

Ablynx to present additional data for its anti-IL-6R nanobody, vobarilizumab, at the annual European Congress of Rheumatology

Read more

Belgium showcases expertise on Immunotherapy at the world’s largest Biotechnology Conference – San Diego, June 19- 23, 2017

Read more

Galapagos' R&D Update 2017: rapidly advancing our product candidates

Read more

Ablynx initiates a single and multiple dose phase I study of caplacizumab in healthy Japanese subjects

Read more

The annual CRIG industrial partnering event

Read more

GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

Read more

Navigation and spatial memory: new brain region identified to be involved

Read more

argenx announces publication of preclinical data supporting the therapeutic potential of SIMPLE AntibodyTM ARGX-116

Read more

Press Release - Life Sciences & Biotechnology

Read more

Bijlage bij Knack vandaag: Fokus Research & Development

Read more

Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million

Read more

Genohm announced today the signing of several new clients

Read more

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

Read more

Ablynx announces positive topline results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP

Read more

Imec Reports Micro-Optomechanical Pressure Sensor Advancing Pressure Monitoring in Biomedical Applications

Read more

Imec Leverages the Power of Silicon Fabrication to Create Innovative Neural Probe Demonstrator with Unprecedented Electrode Density

Read more

Scientists pinpoint surprising origin of melanoma

Read more

Ablynx establishes subsidiary in the USA and appoints a general manager

Read more

Bridging Preclinical and Clinical Development

Read more

Galapagos moving forward in CF programs at NACFC 2017

Read more

Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study

Read more

OCTIMET Oncology NV awarded €1.12 million grant from VLAIO

Read more

Galapagos initiates Phase 1 study with novel CF corrector GLPG3221

Read more

Ablynx - Results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP selected for presentation in the late-breaking abstracts session at the 2017 ASH annual meeting

Read more

Ablynx to host webcast about Phase III Hercules Study

Read more

Galapagos to enter NASDAQ Biotech Index

Read more

Galapagos NV - Transparency notification

Read more

Ablynx reports additional clinically important benefits of Caplacizumab from its Phase III Hercules Study in acquired TTP

Read more

Galapagos Transparency notification

Read more

Ablynx announces positive data from its Japanese ethno-bridging study of Caplacizumab

Read more

Galapagos - Update on progress in cystic fibrosis programs

Read more

iTeos Therapeutics Regains Worldwide Rights to Clinical-Stage IDO1 Inhibitor

Read more

ViroVet wins “start-up of the year” award

Read more

MDxHealth (R): Develops Blood Test to Guide Precision-Treatment of Castration-Resistant Prostate Cancer Patients

Read more

Closing in on Tau: Researchers identify a new synaptic player in early stages of neurodegeneration

Read more

HDAC6 inhibitors protect against neuronal damage and have therapeutic potential in both neurology and oncology

Read more

Imec Introduces CMOS Chip With 16,384 Micro-electrodes and 1,024 Channels for Multimodal Cell Interfacing

Read more

Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego

Read more

MDxHealth financial results

Read more

Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer’s disease

Read more

CMAST to participate in the bio-europe spring partnering conference

Read more

Galapagos publication of the annual report and invitation to the annual shareholders' meeting

Read more

ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317, an anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)

Read more

Galapagos announces ISABELA Phase 3 program in IPF

Read more

Galapagos creates new warrant plan

Read more

Galapagos reports initiation of FALCON clinical trial in cystic fibrosis

Read more

Biocartis Q1 2018 business update

Read more

Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients

Read more

Imec demonstrates direct optical reading of single-molecule DNA bases in modified nanopores

Read more

Flanders.bio appoints new management team to step up its strategy

Read more

GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS

Read more

Imec Packs New Fast Eye Tracking Technology into Ergonomic Design for High-Quality AR/VR Experiences

Read more

Gilead and Galapagos announce results with filgotinib in the phase 2 equator study in psoriatic arthritis and progression into phase 3 for the selection study in ulcerative colitis

Read more

Imec demonstrates compact low-power 140GHz CMOS radar with on-chip antennas

Read more

Galapagos Transparency notification

Read more

SCK•CEN seminar to discover the latest innovations in nuclear medicine

Read more

Galapagos: Topline results of PELICAN trial and update on triple combo development plans

Read more

Biogazelle appoints Armin Winands as new CEO

Read more

Galapagos announces design for PINTA Phase 2 trial with GLPG1205 in IPF

Read more

Immunity for Health

Read more

ELIXIR Innovation and SME Forum

Read more

MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

Read more

ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study

Read more

Biocartis Group NV: Study Abstract on Performance of Idylla(TM) RAS tests Selected for Oral Presentation at 70th AACC Annual Scientific Meeting in Chicago, IL (US)

Read more

Communicating Toxicology: What’s the Risk ?

Read more

GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT

Read more

Gilead and Galapagos announce filgotinib meets primary and all key secondary endpoints in first phase 3 study in rheumatoid arthritis

Read more

MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner

Read more

Galapagos announces launch of proposed public offering

Read more

Galapagos raises $300 million gross proceeds in a U.S. public offering

Read more

Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

Read more

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €296.2 million

Read more

Galapagos issues new shares as result of public offering

Read more

ViroVet receives grant from VLAIO (Flanders) to boost the development of its disruptive vaccine technology

Read more

Galapagos phase 3 data on filgotinib in biologic-experienced rheumatoid arthritis to be presented at 2018 ACR/ARHP annual meeting

Read more

Galapagos: Positive trial results with filgotinib in psoriatic arthritis and ankylosing spondylitis both published in the lancet

Read more

Galapagos: Topline interim results of FALCON trial Part 1 in CF

Read more

Galapagos and AbbVie restructure CF collaboration

Read more

argenx reports third quarter 2018 financial results and provides business update

Read more

Bone Therapeutics announces appointment of Linda Lebon as Chief Regulatory Officer

Read more

Mithra signs exclusive license and supply agreement with Adcock Ingram for commercialization of Estelle® in Southern Africa

Read more

Imec Releases Neuropixels Neural Probe to the Global Neuroscience Community

Read more

Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Read more

Convert Pharmaceuticals appoints Mariola Söhngen as new CEO

Read more

Inbiose secures €4 million in debt financing

Read more

New project launched to harmonize Clinical Data and develop a 21st Century Ecosystem for Real World Health Research in Europe

Read more

Galapagos transparency notification

Read more

Dirk Reyn has been appointed as chairman of the Board of Directors of flanders.bio

Read more

argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia

Read more

MyCartis to engage in point-of-need testing with the ANTELOPE Dx platform technology

Read more

Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Read more

Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis

Read more

Galapagos starts first Phase 1 trial with Toledo compound

Read more

Sands Capital reports 5.7% holding in Galapagos

Read more

FDA Approves OCTIMET’s Investigational New Drug Application to evaluate OMO-1 in patients

Read more

Pharmafluidics’ new product launch steers ‘on-a-chip’ separations of complex biological samples to new heights

Read more

FAIRplus: new project to improve data sharing and reuse in life sciences research

Read more

OCTIMET has determined proof of target engagement in patient tumour tissue and a recommended phase II dose with OMO-1

Read more

Naar een coöperatief model voor de Life Sciences: Antleron wijst de weg

Read more

European Biotech Week

Read more

The Innovative Medicines Initiative launches a public-private coordination and support action

Read more

GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY

Read more

GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)

Read more

Publication of the annual report and invitation to the annual shareholders' meeting

Read more

Structure of the molecular machine that links carbohydrate and lipid metabolism

Read more

V-Bio Ventures leads AgomAb Therapeutics’ 21m EUR series A financing round

Read more

Galapagos creates new warrant plans

Read more

Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients

Read more

Galapagos reports on historic first quarter 2019

Read more

Bootcamp in Rare Diseases

Read more

Terrific year for Belgian biotech companies

Read more

OCTIMET Oncology announces the appointment of Shelley Margetson as CEO

Read more

argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day

Read more

Winnaar van de Dr. Paul Janssen Award voor Biomedisch Onderzoek bekend

Read more

Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa

Read more

Gilead announces intent to submit new drug application for filgotinib to U.S. food and drug administration this year

Read more

VIB: Stripping down bacterial armor: a new way to fight anthrax

Read more

VIB: Using ketone bodies in the fight against lymphedema

Read more

De 2019 Dr. Paul Janssen Award voor Biomedisch Onderzoek voor F.-Ulrich Hartl en Arthur Horwich

Read more

Flanders @ BIO International Convention 2017

Read more

Symposium on Sepsis

Read more

13th International Conference on Renewable Resources & Biorefineries

Read more

Ablynx announces warrant exercise

Read more

Genohm releases the new version v5.4 of SLims

Read more

Mithra to Initiate PK Study for Estelle®

Read more

Ablynx to present at upcoming USA Investor Conferences

Read more

SLims by Genohm integrated with Pathomation’s PMA.core

Read more

Mithra & Gynial sign commercialization agreement for MyringTM in Austria

Read more

Mithra Receives GMP Approval for Myring™ Production

Read more

Mithra Obtains Marketing Authorization for Tibelia® in France

Read more

Towards the Future: Synergizing Efforts for the Next Generation of Cell Therapeutics

Read more

Mithra Signs Exclusive Agreement for Tibelia® in Canada

Read more

Mithra Receives Orphan Drug Designation from EMA for E4 in Neonatal Encephalopathy

Read more

TiGenix announces final equity payment for cardiac platform acquisition

Read more

Services

Read more

Mithra Successfully Raises €26.1 Million

Read more

Mithra Signs Exclusive License and Supply Agreement with Fuji Pharma for Donesta® in Japan and Asean

Read more

Membership Information

Read more

Publication in accordance with art. 14 of the Belgian Law regarding the publication of major shareholdings (the "transparancy law")

Read more

MDxHealth Launches AssureMDx for Bladder Cancer Liquid Biopsy Test

Read more

Daily Newsflash- 10/07/2017

Read more

Ablynx proposes appointment of Mrs. Hilde Windels as a new independent director

Read more

Mithra Submits Myring™ for European Marketing Approval

Read more

Mithra: Recruitment Completed in Estelle® Population PK Substudy

Read more

Ablynx will announce its 2017 half year results with webcast on 24 august 2017

Read more

Mithra Announces First Subject Completes Estelle® Phase III Study

Read more

Ablynx: publication in accordance with article 14 of the Belgian law regarding the publication of major shareholdings

Read more

Ablynx to present at upcoming investor conferences in London

Read more

OPINNO educational module: What does it take to work in a life sciences company?

Read more

Ablynx Announces Warrant Exercise

Read more

Mithra announces 2017 half year results

Read more

Ablynx files registration statement for a proposed global offering

Read more

Ablynx - Publication in accordance with art.14 of the Belgian law of 2/05/2017 regarding the publication of major shareholdings (the "transparancy law")

Read more

Mithra’s Marketing Authorization Application for Tibelia® Accepted by Health Canada

Read more

Ablynx - Publication in accordance with art.14 of the Belgian Law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy law")

Read more

Mithra Announces Completion of Recruitment in Donesta® Phase II Study

Read more

Ablynx announces launch of proposed global offering

Read more

Ablynx prices $200 million Initial Public Offering in the United States

Read more

Suspension of trading in Ablynx shares on Euronext Brussels

Read more

Ablynx - Notice in Relation to the Convertible bonds due May 2020

Read more

Ablynx announces full exercise of underwriters' option to purchase additional shares and end of stabilization period

Read more

MyCartis appoints Philippe Stas as CEO

Read more

Ablynx closes $200 Million Initial Public Offering in the United States

Read more

Mithra Completes Recruitment for Estelle® Phase III Study in US and Canada

Read more

Mithra Announces Launch of Warrant Exercise Period

Read more

Ablynx closes on underwriters' option to purchase $30 million of additional shares in the U.S. initial public offering

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

Ablynx - Correction of Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law) (1)

Read more

Ablynx to present at upcoming investor conferences in London and Paris

Read more

Ablynx: publication regarding the publication of major shareholdings

Read more

Ablynx: publication regarding the publication of major shareholdings (the "transparancy law")

Read more

Ablynx announces results for the first nine months of 2017 and a year-to-date business update

Read more

Mithra Announces Positive Outcome of Myring™ Commercial Batch Bioequivalence Study

Read more

Mithra Announces 36-month Shelf Life Extension for Tibelia®

Read more

A Practical Guide to MiFID II

Read more

Publication of a Transparency Notification Received by Mithra Pharmaceuticals sa/nv

Read more

Ablynx - Publication in accordance with §14 of the Belgian Law

Read more

Mithra Confirms Conversion of Subscription Rights

Read more

Mithra Provides Update on Estelle® and Donesta® Studies

Read more

Daily Newsflash- 5/12/2017

Read more

Mithra Announces Valorization of French Subsidiary

Read more

Persbericht - Life Sciences & Biotechnologie - 14/12/2017

Read more

Mithra Announces Injectables Agreement with GSP

Read more

Trainings - 19/12/2017

Read more

Make your perfect pitch for Life Sciences investors

Read more

Ablynx - notice in relation to waiver of lock-up restriction

Read more

Mithra and Adamed Sign Commercialization Agreement for MyringTM in the Czech Republic

Read more

Ablynx to present at the 36th annual J.P. Morgen Healthcare conference

Read more

Ablynx strongly believes unsolicited conditional proposal from Novo Nordisk fundamentally undervalues the company and its future prospects

Read more

Ablynx announces board changes

Read more

Trainings - 15/01/2018

Read more

BARC and Biogazelle announce collaboration for advanced genetic testing in clinical trials

Read more

Press Release - Life Sciences & Biotechnology - 17/01/2018

Read more

Persbericht - Life Sciences & Biotechnologie - 17/01/2018

Read more

Ablynx appoints dr. Robert Friesen as Chief Scientific Officer

Read more

Mithra Announces Last Subject Completes Donesta® Phase II Study

Read more

Mithra announces very promising hemostasis results for Estelle®

Read more

Ablynx announces 2017 full year results

Read more

Key Considerations in Health Care Product Development

Read more

Networking - 28/02/2018

Read more

European Union provides Biocartis with up to EUR 24m debt financing facility for infectious disease projects

Read more

Ablynx commences dosing in its Phase II Study of ALX-0171 in hospitalised Japanese infants with a RSV infection

Read more

Mithra Reports 2017 Annual Results

Read more

Mithra presents positive hemostasis results at ISGE conference

Read more

Argenx awarded €2.5 million VLAIO grant to identify novel therapeutic antibodies

Read more

MITHRA and ALVOGEN sign LSA for vaginal contraception ring in Russia

Read more

Argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseases

Read more

Mithra Announces Completion of Estelle® Cycles Required in Phase III Contraception Studies

Read more

Mithra applies for additional estelle® patent based on positive hemostasis data

Read more

ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes

Read more

Ablynx teams up with AIM for the design and implementation of its commercial supply chain for caplacizumab

Read more

Promethera Biosciences Acquires Baliopharm AG to Strengthen its Therapeutic Strategy in NASH With a Unique Tumor Necrosis Factor Receptor 1 (TNF-R1) Antibody Drug Candidates

Read more

Promethera Biosciences Raised Additional EUR 9.3 Million to Advance a Broad Product Pipeline in Severe Liver Diseases

Read more

Hamilton Robotics first company to join the UgenTec’s new Molecular Automation Network

Read more

Mithra signs principle agreement for commercialization of Estelle® in canada

Read more

Promethera Biosciences Presents Novel Data on HepaStem’s Ability to Reduce Key Disease Parameters in Advanced Stage NASH in vivo Model

Read more

Mithra releases 2017 Annual Report and invitation to its Ordinary General Shareholders' Meeting

Read more

Ablynx publication in accordance with article 14 of the belgian law of 2 may 2007

Read more

Ablynx completes patient recruitment in the Phase IIb Respire Study of its inhaled anti-RSV Nanobody ALX-0171

Read more

Ablynx announces Warrant Exercise

Read more

Agilent Technologies to Enhance Lab Informatics with Acquisition of Genohm

Read more

Daily newsflash - 03/05/2018

Read more

Sanofi and Ablynx announce the successful results of the initial tender offer period for ablynx and commencement of squeeze-out tender period

Read more

Promethera Biosciences Establishes Branch Office in Tokyo

Read more

Press Release - Life Sciences & Biotechnology - 15/05/2018

Read more

Mithra announces injectable contract with Midas Pharma

Read more

GST raises EUR 5 million to develop veterinary stem cell products

Read more

ProDigest: PROMISE

Read more

Press Release - Life Sciences & Biotechnology - 23/05/2018

Read more

Ablynx: Notice In Relation To The Convertible Bonds Due May 2020

Read more

Update on mithra and mayne pharma’s vaginal contraceptive ring opportunity

Read more

Mithra announces further positive phase IBB Donesta® efficacy and safety data

Read more

Mithra successfully raises eur 77.5 million

Read more

Mithra: information on the total number of voting rights

Read more

Mithra Announces Presentation of Donesta® Results at the International Menopause Society’s 16th World Congress

Read more

Sanofi complets its acquisition of Ablynx following the expiration of the squeeze-out procedure

Read more

Daily newsflash - 29/06/2018

Read more

Mithra: Publication of a Transparency Notification Received from François Fornieri

Read more

Mithra and Mediner sign LSA for Tibelia® in Hungary

Read more

Mithra Obtains First Marketing Authorization for Myring™ in Europe

Read more

Mithra announces belux agreement with ceres pharma worth over eur 40 million

Read more

Promethera Biosciences Appoints Mutsuki Takano as General Manager of its Branch Office in Tokyo

Read more

Mithra announces positive top-line results of estelle® phase III oral contraceptive study in eu/russia

Read more

NEW EARLY PHASE CLINICAL TRIALS PARADIGM - 6TH BIOPHARM DAY SEMINAR

Read more

Lessons in Herding Cats: Business Development for Life Science Companies

Read more

Mithra announces further details regarding contract gedeon richter

Read more

Press Release - Life Sciences & Biotechnology - 18/09/2018

Read more

Mithra signs exclusive license and supply agreement for commercialization of Tibelia® in Taiwan

Read more

Mithra Announces 2018 Half Year Results

Read more

Mithra Signs Exclusive License And Supply Agreement For The Commercialization Of Myring™ In Chile With Laboratorio Pasteur

Read more

Presentation of Donesta® PHIIB results at the 2018 annual meeting of the North American menopause society

Read more

Mithra: 2018 update and 2019 outlook given at the cphi conference

Read more

Dutch Life Sciences conference

Read more

BioTrinity 2019

Read more

Mithra Announces the Completion of its Lead Clinical Phase III Programme for Estelle®

Read more

Mithra: full Estetrol (E4) program update provided at scientific advisory board meetings

Read more

Mithra signs exclusive license and supply agreement for vaginal contraceptive ring in Australia and New Zealand

Read more

Mithra reduces environmental impact of CDMO facility in Belgium with the installation of 1800 solar panels

Read more

Flanders @ BIO International Convention 2019

Read more

Mithra Announces Positive Results of Ovarian Function Sub-Study which Strengthens Estelle® Contraceptive Efficacy Profile

Read more

Mithra announces Myring™ update

Read more

Promethera Biosciences Announces Investment by ITOCHU Corporation and a Broad Strategic Collaboration to Access the Asian Markets

Read more

Mithra Announces Attendance at the 37th Annual J.P. Morgan Healthcare Conference

Read more

Blockbuster Potential in Perimenopause with new E4 Candidate and Acceleration of Donesta Phase III Program

Read more

Mithra wins BelMid Company of the Year 2018

Read more

Mithra announces 2019 financial calendar

Read more

IQVIA, QbD and Select enter into a strategic partnership with flanders.bio as of January 1st, 2019

Read more

Mithra Announces Positive Top-line Results of Estelle® Phase III Oral Contraceptive Study in U.S/Canada

Read more

Mithra Strengthens Management Team With Key Appointments

Read more

Mithra Signs Exclusive License and Supply Agreement for Commercialization of Myring™ in the Middle East

Read more

Talent accelerator programme for biobusiness

Read more

Mithra Announces New Polymer Technology Development for a Leading Veterinarian Company

Read more

Mithra Signs License and Supply Agreement for Commercialization of Tibelia® in Chile

Read more

flanders.bio supports HIHR

Read more

Mithra Demonstrates Further Estetrol’s Unique Profile at the Annual Meeting of the Endocrine Society

Read more

Genkyotex Reverse Stock Split Takes Effect

Read more

Mithra receives Orphan Drug Designation from FDA for E4 in neonatal encephalopathy treatment

Read more

Mithra wins essenscia Innovation Award 2019 for its new generation contraceptive pill, Estelle®

Read more

Mithra announces new agreement with GSP for development of an additional injectable

Read more

Mithra Signs License and Supply Agreement for Commercialization of Myring™ in Latin and South America

Read more

ActoBio Therapeutics™’ CTO Lothar Steidler Elected VIB Alumni Awardee 2019

Read more

Promethera Biosciences Announces First-Dosing in Phase 2a Clinical Study Evaluating World’s First Liver Stem Cell Therapy in Late-Stage NASH Patients

Read more

Mithra Signs LSA for Commercialization of Myring™ in Germany, the biggest market in Europe

Read more

Biocartis and Kite Sign Agreement for Development of Assays supporting Kite's Therapies

Read more

PMV is stepping into a strategic partnership with flanders.bio as of June 1st, 2019

Read more

ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes

Read more

AgroSavfe appoints Patrice Sellès as new Chief Executive Officer and further strengthens leadership team

Read more

Women Startup Challenge Europe HealthTech

Read more

Mithra CDMO Strengthens its Management Team and Accelerates Key R&D Programs

Read more

Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF

Read more

Janssen Pharmaceutica investeert 21 miljoen euro in “productie van de toekomst” op de Janssen Campus in Beerse

Read more

Bone Therapeutics Strengthens Board of Directors

Read more